PD-1 Blockade in Anaplastic Thyroid Carcinoma.

ABSTRACT:

Purpose

Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor.

Methods

We enrolled patients with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study. Patients received 400 mg spartalizumab intravenously, once every 4 weeks. The overall response rate was determined according to RECIST v1.1.

Results

Forty-two patients were enrolled. Adverse events were consistent with

SUBMITTER: Capdevila J 

PROVIDER: S-EPMC7476256 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature